This study is designed to investigate the possible beneficial effects of UDCA on liver graft recovery early after adult liver transplantation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
112
13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
Shanghai First People's Hospital
Shanghai, Shanghai Municipality, China
Serum liver tests
Serum liver tests include serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), alkaline phosphatase (ALP) and total bilirubin (TB)
Time frame: within the first 4 weeks after liver transplantation
Postoperative complications
Postoperative complications include rates of acute cellular rejection (ACR), drug-induced hepatotoxicity, vascular or biliary complications, recurrence of primary liver disease and death
Time frame: within the first 4 weeks after liver transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.